Traws Pharma, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-12-31 was $0.00.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-09-30 was $111.62M.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-12-31 was $15.00K, a 94.62% decline year-over-year.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $111.62M.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $495.00K, a 95.19% decline from fiscal 2020.
- Traws Pharma, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $10.29M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $111.62M 10-K · filed 2026-04-15 |
| 2024-09-30 | $111.62M 10-Q · filed 2025-11-13 | |
| 2021-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $495.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $759.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $3.48M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $480.00K 10-Q · filed 2022-05-13 | $5.06M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $10.29M 10-K · filed 2022-03-21 |
| 2020-09-30 | $2.72M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $1.58M 10-Q · filed 2021-08-16 | |
| 2020-03-31 | $5.72M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |